Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

The booming uptake of anti-obesity drugs in India is further underscored by rising momentum of Eli Lilly's Mounjaro, which ...

Trend alert! Split dosing, stretch dosing, skip dosing, microdosing Ozempic… People are finding creative ways to use ...

Wegovy, a weight loss drug which reduces cardiovascular risks in obese individuals, launched in India on June 24. Experts ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, Managing Director of Novo Nordisk India, in an interview with Moneycontrol.

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related events in adults with established cardiovascular diseases. From cost to availabi ...

Novo Nordisk decodes India’s obesity drug market with Wegovy positioned as once-a-week novel weight management medication: Our Bureau, Bengaluru Tuesday, June 24, 2025, 15:45 Hr ...

The drug will follow a four-week cycle for dosage, starting with the smallest dose of 0.25 mg per week for four weeks, followed by a gradual increase in dosage.

Missing your Ozempic dose occasionally may not cause serious harm, but repeatedly skipping it may cause an increased risk of diabetes complications.